These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8953654)

  • 1. Crystallization of the receptor binding domain of vascular endothelial growth factor.
    Christinger HW; Muller YA; Berleau LT; Keyt BA; Cunningham BC; Ferrara N; de Vos AM
    Proteins; 1996 Nov; 26(3):353-7. PubMed ID: 8953654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
    Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
    J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
    Meyer M; Clauss M; Lepple-Wienhues A; Waltenberger J; Augustin HG; Ziche M; Lanz C; Büttner M; Rziha HJ; Dehio C
    EMBO J; 1999 Jan; 18(2):363-74. PubMed ID: 9889193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification and refolding of vascular endothelial growth factor-B.
    Scrofani SD; Fabri LJ; Xu P; Maccarone P; Nash AD
    Protein Sci; 2000 Oct; 9(10):2018-25. PubMed ID: 11106176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
    Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1H, 13C, and 15N backbone assignment and secondary structure of the receptor-binding domain of vascular endothelial growth factor.
    Fairbrother WJ; Champe MA; Christinger HW; Keyt BA; Starovasnik MA
    Protein Sci; 1997 Oct; 6(10):2250-60. PubMed ID: 9336848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states.
    Starovasnik MA; Christinger HW; Wiesmann C; Champe MA; de Vos AM; Skelton NJ
    J Mol Biol; 1999 Oct; 293(3):531-44. PubMed ID: 10543948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
    Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
    Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
    Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
    Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF.
    Keck RG; Berleau L; Harris R; Keyt BA
    Arch Biochem Biophys; 1997 Aug; 344(1):103-13. PubMed ID: 9244387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
    Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
    Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding.
    Iyer S; Scotney PD; Nash AD; Ravi Acharya K
    J Mol Biol; 2006 May; 359(1):76-85. PubMed ID: 16616187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
    Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
    Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor: possible role in fetal development and placental function.
    Cheung CY
    J Soc Gynecol Investig; 1997; 4(4):169-77. PubMed ID: 9292845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
    Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.